CompletedNot Applicable

A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Guinea-Bissau3,812 participantsStarted 2016-10

Plain-language summary

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Who can participate

Age range18 Months – 24 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination. Exclusion Criteria: * Having severe malformations that impairs their health * Having received a second dose of measles vaccine * Severely ill (requiring hospitalization) upon clinical examination

What they're measuring

Mortality

Timeframe: 30 months

Hospital admissions

Timeframe: 30 months

Trial details

NCT IDNCT02943681

SponsorBandim Health Project

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05

View on ClinicalTrials.gov More Child Mortality trials